Loading...
XNYS
LLY
Market cap782bUSD
Mar 31, Last price  
825.39USD
1D
0.35%
1Q
6.92%
Jan 2017
1,022.22%
Name

Eli Lilly and Co

Chart & Performance

D1W1MN
P/E
73.89
P/S
17.37
EPS
11.17
Div Yield, %
0.47%
Shrs. gr., 5y
-0.69%
Rev. gr., 5y
15.08%
Revenues
45.04b
+32.00%
14,645,300,00015,691,000,00018,633,500,00020,378,000,00021,836,000,00023,076,000,00024,286,500,00022,603,400,00023,113,100,00019,615,600,00019,958,700,00021,222,100,00022,871,300,00021,493,300,00022,319,500,00024,539,800,00028,318,400,00028,541,400,00034,124,100,00045,042,700,000
Net income
10.59b
+102.08%
1,979,600,0002,662,700,0002,953,000,000-2,071,900,0004,328,800,0005,069,500,0004,347,700,0004,088,600,0004,684,800,0002,390,500,0002,408,400,0002,737,600,000-204,100,0003,232,000,0004,637,900,0006,193,700,0005,581,700,0006,244,800,0005,240,400,00010,590,000,000
CFO
8.82b
+107.96%
1,913,600,0003,975,900,0005,154,500,0007,295,600,0004,335,500,0006,856,800,0007,234,500,0005,304,800,0005,735,000,0004,367,100,0002,772,800,0004,851,000,0005,615,600,0005,524,500,0004,836,600,0006,499,600,0007,260,700,0007,084,400,0004,240,100,0008,817,900,000
Dividend
Feb 14, 20251.5 USD/sh
Earnings
Apr 28, 2025

Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
URL
https://www.lilly.com/
IPO date
Jul 09, 1970
Employees
39,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
45,042,700
32.00%
34,124,100
19.56%
28,541,400
0.79%
Cost of revenue
19,408,900
23,336,800
21,261,000
Unusual Expense (Income)
NOPBT
25,633,800
10,787,300
7,280,400
NOPBT Margin
56.91%
31.61%
25.51%
Operating Taxes
2,090,400
1,314,200
561,600
Tax Rate
8.15%
12.18%
7.71%
NOPAT
23,543,400
9,473,100
6,718,800
Net income
10,590,000
102.08%
5,240,400
-16.08%
6,244,800
11.88%
Dividends
(4,680,400)
(4,069,300)
(3,535,800)
Dividend yield
0.67%
0.77%
1.07%
Proceeds from repurchase of equity
(2,500,000)
(750,000)
(1,500,000)
BB yield
0.36%
0.14%
0.45%
Debt
Debt current
6,904,500
1,501,100
Long-term debt
19,428,200
14,737,500
Deferred revenue
Other long-term liabilities
36,066,700
7,528,600
6,751,400
Net debt
(6,484,300)
20,352,800
11,125,000
Cash flow
Cash from operating activities
8,817,900
4,240,100
7,084,400
CAPEX
(5,057,800)
(3,447,600)
(2,484,000)
Cash from investing activities
(9,301,500)
(7,152,700)
(3,261,600)
Cash from financing activities
1,230,100
3,495,600
(5,406,700)
FCF
50,611,200
629,300
6,403,700
Balance
Cash
3,268,400
2,927,700
2,211,800
Long term investments
3,215,900
3,052,200
2,901,800
Excess cash
4,232,165
4,273,695
3,686,530
Stockholders' equity
14,832,400
6,670,700
6,917,700
Invested Capital
46,106,135
39,343,905
29,603,770
ROIC
55.10%
27.48%
23.31%
ROCE
50.92%
24.73%
21.81%
EV
Common stock shares outstanding
904,059
903,284
904,619
Price
772.00
32.44%
582.92
59.34%
365.84
32.45%
Market cap
697,933,548
32.55%
526,542,309
59.10%
330,945,815
31.42%
EV
691,449,248
546,986,909
342,196,415
EBITDA
25,633,800
12,314,600
8,802,900
EV/EBITDA
26.97
44.42
38.87
Interest
605,400
485,900
331,600
Interest/NOPBT
2.36%
4.50%
4.55%